NO20053071L - Kalsilytiske forbindelser. - Google Patents

Kalsilytiske forbindelser.

Info

Publication number
NO20053071L
NO20053071L NO20053071A NO20053071A NO20053071L NO 20053071 L NO20053071 L NO 20053071L NO 20053071 A NO20053071 A NO 20053071A NO 20053071 A NO20053071 A NO 20053071A NO 20053071 L NO20053071 L NO 20053071L
Authority
NO
Norway
Prior art keywords
calcilitic
compounds
new
methods
new calcilitic
Prior art date
Application number
NO20053071A
Other languages
English (en)
Other versions
NO332304B1 (no
Inventor
James Francis Callahan
Robert W Marquis
Linda N Casillas
Joshi M Ramanjulu
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20053071L publication Critical patent/NO20053071L/no
Publication of NO332304B1 publication Critical patent/NO332304B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nye kalsilytiske forbindelser og fremgangsmåter for anvendelse av dem er tilveiebrakt.
NO20053071A 2002-11-26 2005-06-22 Kalsilytiske forbindelser. NO332304B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42910502P 2002-11-26 2002-11-26
PCT/US2003/037461 WO2004047751A2 (en) 2002-11-26 2003-11-25 Calcilytic compounds

Publications (2)

Publication Number Publication Date
NO20053071L true NO20053071L (no) 2005-06-22
NO332304B1 NO332304B1 (no) 2012-08-20

Family

ID=32393505

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053071A NO332304B1 (no) 2002-11-26 2005-06-22 Kalsilytiske forbindelser.

Country Status (32)

Country Link
US (6) US7514473B2 (no)
EP (1) EP1569892B1 (no)
JP (1) JP4489597B2 (no)
KR (2) KR101142697B1 (no)
CN (1) CN1325466C (no)
AP (1) AP2113A (no)
AR (1) AR042132A1 (no)
AU (1) AU2003291157C1 (no)
BR (1) BR0316544A (no)
CA (1) CA2507226C (no)
CO (1) CO5570664A2 (no)
CY (1) CY1113083T1 (no)
DK (1) DK1569892T3 (no)
EA (1) EA009603B1 (no)
ES (1) ES2388277T3 (no)
IL (1) IL168704A (no)
IS (1) IS2897B (no)
MA (1) MA27528A1 (no)
MX (1) MXPA05005574A (no)
MY (1) MY143244A (no)
NO (1) NO332304B1 (no)
NZ (1) NZ540275A (no)
OA (1) OA12962A (no)
PE (1) PE20040845A1 (no)
PL (1) PL211571B1 (no)
PT (1) PT1569892E (no)
SI (1) SI1569892T1 (no)
TW (1) TWI316511B (no)
UA (1) UA81642C2 (no)
UY (1) UY28089A1 (no)
WO (1) WO2004047751A2 (no)
ZA (1) ZA200504104B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY143244A (en) * 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
US20070155819A1 (en) * 2004-02-06 2007-07-05 Marquis Robert W Jr Calcilytic compounds
TW200845956A (en) * 2006-12-18 2008-12-01 Smithkline Beecham Corp Calcilytic compounds
CA2726610C (en) * 2008-06-05 2015-05-05 Asahi Kasei Pharma Corporation Sulfonamide compounds and use thereof
NZ593676A (en) * 2008-12-24 2012-06-29 Daiichi Sankyo Co Ltd Calcium-sensing receptor antagonists
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
WO2015196205A1 (en) * 2014-06-20 2015-12-23 Glaxosmithkline Llc Method of using calcilytic compounds to treat diseases of abnormal glucose or insulin levels

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE298506C (no)
US643656A (en) * 1898-09-03 1900-02-20 Francis Keil Mold for lock-cylinders and key-hubs.
ES421076A1 (es) 1973-12-01 1976-04-01 Andreu Sa Dr Procedimiento para la obtencion de 1-ariloxi-3-aralquilami-no-2-propanoles.
ES442062A1 (es) 1975-10-24 1977-04-01 Andreu Sa Dr Procedimiento para la obtencion de 1-ariloxi-2-hidroxi-3- alquilaminopropanos.
DE2644833A1 (de) * 1976-10-05 1978-04-20 Boehringer Sohn Ingelheim Neue 1-aryloxy-2-hydroxy-3-alkylenaminopropane und verfahren zu ihrer herstellung
CH618335A5 (no) * 1977-05-31 1980-07-31 Arnegger Richard E
US4234595A (en) * 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
IT1101724B (it) * 1978-12-05 1985-10-07 Erba Carlo Spa Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione
GB2014968A (en) 1978-02-24 1979-09-05 Pearson J Article handling apparatus
US4495352A (en) * 1979-02-13 1985-01-22 Mead Johnson & Company Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
ES480066A1 (es) 1979-04-28 1980-04-01 Especialid Latin Medicam Unive Procedimiento de obtencion de 1-4-cloro-&,&-dimetil-benceno-etanamino-2-oxi-3 ariloxi propanos.
DE3544172A1 (de) * 1985-12-13 1987-06-19 Lentia Gmbh Neue kristalline salze von aryloxy-propanolaminen, verfahren zu ihrer herstellung und ihre verwendung
FR2601008B1 (fr) * 1986-07-03 1990-03-30 Sanofi Sa Procede de synthese stereospecifique de derives de l'indole
DD298506A5 (de) * 1988-12-30 1992-02-27 Ernst-Moritz-Arndt-Universitaet Greifswald,De Verfahren zur herstellung halogensubstituierter 1-phenoxy-3-alkylamino-propan-2-ole
DE4040186A1 (de) 1989-12-20 1991-06-27 Hoechst Ag Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6818660B2 (en) * 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
SG99290A1 (en) 1996-04-09 2003-10-27 Nps Pharma Inc Calcilytic compounds
US20020019440A1 (en) * 1996-11-05 2002-02-14 Virbac Sa Aryloxypropanolamine derivatives, method of preparation and applications thereof
TW483881B (en) * 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
US7202261B2 (en) * 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
JP2001519813A (ja) 1997-04-04 2001-10-23 スミスクライン・ビーチャム・コーポレイション カルシウム溶解性化合物
UY24949A1 (es) * 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
DE19913753A1 (de) 1998-04-01 1999-10-07 Mannesmann Rexroth Ag Verfahren zur Bildung des Mittelwertes
AR014975A1 (es) 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
PE20000415A1 (es) 1998-04-08 2000-05-21 Smithkline Beecham Corp Compuestos calciliticos
JP2002522499A (ja) * 1998-08-12 2002-07-23 スミスクライン・ビーチャム・コーポレイション カルシウム分解化合物
WO2000009491A1 (en) * 1998-08-12 2000-02-24 Smithkline Beecham Corporation Calcilytic compounds
PE20001456A1 (es) * 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
WO2001007026A2 (en) 1999-07-22 2001-02-01 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
ECSP003590A (es) 1999-07-31 2002-02-25 Smithkline Beecham Corp Compuestos calcioliticos
AR030684A1 (es) 2000-01-24 2003-09-03 Smithkline Beecham Corp Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
US20030018203A1 (en) * 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
HUP0300758A2 (hu) 2000-07-21 2003-08-28 Smithkline Beecham Corp. Kalcilitikus vegyületek és alkalmazásuk kalciumreceptor antagonistákként
US20040009980A1 (en) 2000-10-25 2004-01-15 Pradip Bhatnagar Calcilytic compounds
WO2002034204A2 (en) 2000-10-25 2002-05-02 Smithkline Beecham Corporation Calcilytic compounds
AU2002254136A1 (en) * 2001-03-08 2002-09-24 Smithkline Beecham Corporation Pcra helicase inhibitors
US6864267B2 (en) * 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
MY143244A (en) * 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
EP1613606A4 (en) * 2003-04-07 2008-12-03 Nps Pharma Inc PROCESS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES
JP2007502831A (ja) * 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
WO2005030746A1 (en) 2003-09-24 2005-04-07 Glaxo Group Limited Calcilytic compounds
AR045799A1 (es) * 2003-09-24 2005-11-16 Glaxo Group Ltd Compuesto 6- oxo-2,5- dioxabiciclico y su uso para preparar una composicion farmaceutica
JP2007523076A (ja) * 2004-02-06 2007-08-16 スミスクライン・ビーチャム・コーポレイション カルシウム受容体アンタゴニスト化合物
NL1025457C1 (nl) 2004-02-11 2005-08-12 Rudolf Johannes Gerardus Hoorn Haspelrem.
EP1814535A4 (en) 2004-11-08 2008-06-04 Nitromed Inc NITROSED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING EYE DISEASES
AU2006206249A1 (en) 2005-01-21 2006-07-27 Nicox S.A. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use

Also Published As

Publication number Publication date
US9227914B2 (en) 2016-01-05
EA009603B1 (ru) 2008-02-28
CY1113083T1 (el) 2016-04-13
US20130158114A1 (en) 2013-06-20
EP1569892B1 (en) 2012-06-13
JP2006507348A (ja) 2006-03-02
TWI316511B (en) 2009-11-01
UY28089A1 (es) 2004-06-30
PT1569892E (pt) 2012-09-06
AU2003291157B2 (en) 2011-01-20
PL211571B1 (pl) 2012-05-31
US20140057980A1 (en) 2014-02-27
US20090163589A1 (en) 2009-06-25
AR042132A1 (es) 2005-06-08
EA200500878A1 (ru) 2005-10-27
JP4489597B2 (ja) 2010-06-23
US8586631B2 (en) 2013-11-19
OA12962A (en) 2006-10-13
IS7880A (is) 2005-06-02
WO2004047751A3 (en) 2004-08-19
CN1741985A (zh) 2006-03-01
EP1569892A2 (en) 2005-09-07
KR20050086786A (ko) 2005-08-30
US20150183723A1 (en) 2015-07-02
US8980950B2 (en) 2015-03-17
WO2004047751A2 (en) 2004-06-10
US7514473B2 (en) 2009-04-07
US7829594B2 (en) 2010-11-09
IS2897B (is) 2014-09-15
AU2003291157A1 (en) 2004-06-18
AP2113A (en) 2010-03-04
HK1082914A1 (en) 2006-06-23
CA2507226A1 (en) 2004-06-10
ZA200504104B (en) 2006-03-29
MA27528A1 (fr) 2005-09-01
CN1325466C (zh) 2007-07-11
CA2507226C (en) 2011-11-15
KR20110124806A (ko) 2011-11-17
TW200510276A (en) 2005-03-16
MXPA05005574A (es) 2005-07-27
SI1569892T1 (sl) 2012-09-28
KR101142697B1 (ko) 2012-05-10
AU2003291157C1 (en) 2011-05-12
NZ540275A (en) 2007-11-30
NO332304B1 (no) 2012-08-20
US8399517B2 (en) 2013-03-19
US20060058391A1 (en) 2006-03-16
US20110054021A1 (en) 2011-03-03
BR0316544A (pt) 2005-10-04
ES2388277T3 (es) 2012-10-11
IL168704A (en) 2010-12-30
EP1569892A4 (en) 2010-09-15
PL376965A1 (pl) 2006-01-09
CO5570664A2 (es) 2005-10-31
UA81642C2 (ru) 2008-01-25
DK1569892T3 (da) 2012-08-27
MY143244A (en) 2011-04-15
PE20040845A1 (es) 2004-11-28
AP2005003320A0 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
NO20043442L (no) Nye substituerte benzimidazol-doseringsformer og fremgangsmater for anvendelse av samme
DK1465615T3 (da) Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
NO20044597L (no) Kjemiske forbindelser
ATE461217T1 (de) Glp-1-verbindungen
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
IS7721A (is) Píperidín-pýrídasón og þalasón sem PDE4 hemlar
DE60301683D1 (de) Leseverstärker
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
ATE474617T1 (de) Medizinproduktsysteme
DK1511734T3 (da) Forbindelser, præparater og fremgangsmåder
NO20044448L (no) Nye forbindelser
NO20045675L (no) Peptiddeformylaseinhibitorer
NO20044898L (no) Nye etonogestrel estere
ITMI20022079A1 (it) Amplificatore di raman.
DE60331026D1 (de) Ramanverstärker
SE0301650D0 (sv) Novel compounds
DE60313304D1 (de) Spreizspektrum-Empfangsvorrichtung
NO20060184L (no) Fremgangsmate for fremstilling av ikke-peptid substituerte spirobenzoazepinderivater
SG145685A1 (en) Matrix metalloproteinase inhibitors
DE60326773D1 (de) Peptid-deformylase-hemmer
DK1663997T3 (da) 1h-azolyl-methyl-amider, fremgangsmåde til fremstilling deraf og anvendelse deraf som nitrifikationsinhibitorer
MXPA05005574A (es) Compuestos calciliticos.
IS7694A (is) Sterasamrunaefnasambönd, framleiðsla og notkun þeirra
IS7441A (is) Peptíðdeformýlasatálmar
AU2003304490A1 (en) Peptide deformylase inhibitors

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees